Science & Technology
A novel inhaled dry powder psychoplastogenic formulation for treating persons with opioid use disorder
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R43DA060713-01
Award Ceiling
$405K
Award Floor
$405K
Close Date
May 31, 2025
Total Funding
$405K
Expected Awards
1
Posted Date
Jun 1, 2024
Cost Sharing Required
No
Grants.gov ID
sbir-1R43DA060713-01
Description
SBIR Phase Phase I award: "A novel inhaled dry powder psychoplastogenic formulation for treating persons with opioid use disorder" awarded to Quench Medical Inc. in Saint Paul, Minnesota. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $404,917. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.